Rationale and design of PURE, a randomized controlled trial to evaluate Peritoneal Ultrafiltration with PolyCore™ in Refractory Congestive Heart Failure.
PURE 研究的理由與設計:一項隨機對照試驗,評估在難治性充血性心衰竭中使用 PolyCore™ 進行腹膜超濾的效果。
Kidney Blood Press Res 2024-08-28
New Miniaturized System for Ultrafiltration: Rationale and Design of a Single-Center, Crossover, Randomized, Open-Label, Pilot Study Protocol.
新型微型超濾系統:單中心、交叉、隨機、開放標籤、初步研究方案的基礎和設計。
Cardiorenal Med 2024-03-19
Rationale and Design of the SOTA-P-CARDIA Trial (ATRU-V): Sotagliflozin in HFpEF Patients Without Diabetes.
SOTA-P-CARDIA試驗(ATRU-V)的理念與設計:Sotagliflozin用於非糖尿病HFpEF患者。
Cardiovasc Drugs Ther 2023-06-15
Rationale and Design of NEUTRALIZE-AKI: A Multicenter, Randomized, Controlled, Pivotal Study to Assess the Safety and Efficacy of a Selective Cytopheretic Device in Patients with Acute Kidney Injury Requiring Continuous Kidney Replacement Therapy.
NEUTRALIZE-AKI 試驗的理念與設計:一項多中心、隨機、對照、關鍵性研究,旨在評估一種選擇性細胞療法裝置對需要持續腎臟替代治療的急性腎損傷患者的安全性和有效性。
Nephron 2024-01-18
Rationale and protocol of the LAQUA-HF trial: a factorial randomised controlled trial evaluating the effects of neurohormonal and diuretic agents on health-status reported outcomes in heart failure patients.
LAQUA-HF試驗的理念和方案:一項隨機分配對照試驗,評估神經荷爾蒙和利尿劑對心臟衰竭患者健康狀況報告結果的影響。
BMJ Open 2024-02-17
Rationale and Design of Prospective, Multicenter, Double-Arm Clinical Trial to Investigate the Efficacy of Tofogliflozin on Left Ventricular Diastolic Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus (TOP-HFPEF Trial).
探討 Tofogliflozin 對心臟衰竭合併保留射血分數及第2型糖尿病患者左心室舒張功能障礙之療效的前瞻性、多中心、雙臂臨床試驗(TOP-HFPEF 試驗)的理念與設計。
Cardiovasc Drugs Ther 2024-05-10
Patiromer to Reduce Albuminuria Through Increased Renin Angiotensin Aldosterone System Inhibition in Patients With CKD-A Feasibility Trial.
Patiromer 透過增加腎素-血管緊張素-醛固酮系統抑制來降低慢性腎病合併糖尿病患者的蛋白尿:可行性試驗。
Kidney Int Rep 2024-08-19
Effect of henagliflozin on left ventricular mass index in dialysis patients with HFpEF (HELD-HF): protocol for a multicentre, randomised, double-blind, placebo-controlled trial.
henagliflozin 對於有 HFpEF 的透析病人左心室質量指數的影響 (HELD-HF):一項多中心、隨機、雙盲、安慰劑對照試驗的研究計劃。
BMJ Open 2024-08-27